Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis

Cancer
Marko StänderFriedrich W Kreth

Abstract

The goal of the current study was to retrospectively assess the prognostic impact of TP53 mutation status and P53 expression/accumulation on long-term outcome for adult patients with supratentorial World Health Organization (WHO) Grade II astrocytoma or oligoastrocytoma. The authors revisited a previously published short-term data set containing information on 159 consecutive patients who were treated between 1991 and 1998. Each patient was screened for TP53 mutations and P53 overexpression/accumulation. The reference point for all analyses was the date of surgical treatment, and the date of last follow-up examination was August 2002. Overall survival, progression-free survival, postrecurrence survival, and time to malignant transformation were estimated using the Kaplan-Meier method, and potential prognostic factors were evaluated using the multivariate proportional hazards model. The median follow-up duration for survivors was 80.4 months (standard deviation, 33.0 months). TP53 mutations, which were present in 49.1% of all tumors, occurred preferentially in gemistocytic tumors (P < 0.05). In addition, the TP53 status of the primary tumor was predictive of the TP53 status of the recurrent tumor in all cases of disease recurren...Continue Reading

Citations

Nov 12, 2005·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Funda CorapçíoğluDeniz Uren
Dec 23, 2008·Journal of Neuro-oncology·Masayuki KanamoriTeiji Tominaga
Sep 8, 2012·Current Treatment Options in Oncology·Adriana Olar, Kenneth D Aldape
Nov 26, 2008·Journal of Neurosurgery·Wei-Ying YueZhong-Ping Chen
Nov 30, 2013·Pharmacology & Therapeutics·Frédéric Checler, Cristine Alves da Costa
Dec 18, 2013·Neuro-oncology·Agustí AlentornAhmed Idbaih
Nov 17, 2010·Acta Neuropathologica·Philippe MetellusDominique Figarella-Branger
Aug 12, 2014·AJNR. American Journal of Neuroradiology·Y Y WangT Jiang
Jan 22, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Kai WangJian-Ping Dai
Oct 30, 2007·Neurologic Clinics·James L FisherJoseph L Wiemels
Aug 13, 2005·Advances in Anatomic Pathology·Christine E Fuller, Arie Perry
Aug 5, 2017·JCI Insight·Joseph E IppolitoJoshua B Rubin
May 18, 2019·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hyemi ShinDo-Hyun Nam
Nov 20, 2012·Current Opinion in Neurology·Markus Weiler, Wolfgang Wick
Aug 7, 2008·Journal of Neuro-oncology·Nader PouratianDavid Schiff
Oct 13, 2009·Expert Review of Molecular Diagnostics·Maria Grazia BruzzoneGaetano Finocchiaro
Aug 15, 2012·Journal of Neuro-oncology·Dominique Figarella-BrangerPhilippe Metellus
Dec 3, 2017·Journal of Neuro-oncology·Eric GoetheNaveen Pemmaraju
Mar 5, 2014·Journal of Neuro-oncology·Emeline GilletAhmed Idbaih
Aug 7, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian HartmannUNKNOWN German Glioma Network
Mar 15, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel GorovetsJason T Huse
May 12, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian HartmannUNKNOWN German Glioma Network
Jun 8, 2021·Molecular Diagnosis & Therapy·Lidia GattoAlba Ariela Brandes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.